![]() |
Name |
Cyclopentane, 4-pentenylidene
|
Molecular Formula | C10H16 | |
IUPAC Name* |
pent-4-enylidenecyclopentane
|
|
SMILES |
C=CCCC=C1CCCC1
|
|
InChI |
InChI=1S/C10H16/c1-2-3-4-7-10-8-5-6-9-10/h2,7H,1,3-6,8-9H2
|
|
InChIKey |
UYISGPPEYKFIKW-UHFFFAOYSA-N
|
|
Synonyms |
Cyclopentane, 4-pentenylidene; 3-[(Z)-2-Phenylethenyl]cholestan-2-one
|
|
CAS | NA | |
PubChem CID | 523531 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 136.23 | ALogp: | 3.3 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 10 | QED Weighted: | 0.403 |
Caco-2 Permeability: | -4.426 | MDCK Permeability: | 0.00002140 |
Pgp-inhibitor: | 0.119 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.933 |
30% Bioavailability (F30%): | 0.968 |
Blood-Brain-Barrier Penetration (BBB): | 0.838 | Plasma Protein Binding (PPB): | 95.11% |
Volume Distribution (VD): | 1.899 | Fu: | 2.43% |
CYP1A2-inhibitor: | 0.917 | CYP1A2-substrate: | 0.379 |
CYP2C19-inhibitor: | 0.393 | CYP2C19-substrate: | 0.333 |
CYP2C9-inhibitor: | 0.325 | CYP2C9-substrate: | 0.872 |
CYP2D6-inhibitor: | 0.116 | CYP2D6-substrate: | 0.86 |
CYP3A4-inhibitor: | 0.25 | CYP3A4-substrate: | 0.168 |
Clearance (CL): | 7.013 | Half-life (T1/2): | 0.407 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.091 |
Drug-inuced Liver Injury (DILI): | 0.036 | AMES Toxicity: | 0.012 |
Rat Oral Acute Toxicity: | 0.028 | Maximum Recommended Daily Dose: | 0.513 |
Skin Sensitization: | 0.919 | Carcinogencity: | 0.903 |
Eye Corrosion: | 0.548 | Eye Irritation: | 0.985 |
Respiratory Toxicity: | 0.192 |